COMPARISON OF COST- EFFICACY OF SUBCUTANEOUS ABATACEPT VERSUS ADALIMUMAB IN THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS

被引：0
|
作者：
Khanna, D. [1 ]
Massarotti, E. [2 ]
Rosenblatt, L. [3 ]
Budd, D. [3 ]
Sabater, J. [4 ]
Hebden, T. [3 ]
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
[2] Brigham & Womens Hosp, Boston, MA 02115 USA
[3] Bristol Myers Squibb Co, Princeton, NJ USA
[4] Bristol Myers Squibb Int, Paris, France
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：340 / 341
页数：2
相关论文
共 50 条
  • [1] COST-PER-RESPONSE ANALYSIS OF SUBCUTANEOUS ABATACEPT VERSUS ADALIMUMAB FOR THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS - BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
    Alves, Nathalie
    Marinheiro, Paola
    Bemardino, Graziela
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2019, 25 : S41 - S41
  • [2] Head to Head Comparison of Subcutaneous Abatacept Versus Adalimumab in the Treatment of Rheumatoid Arthritis: Key Efficacy and Safety Results From the Ample (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) Trial
    Weinblatt, Michael E.
    Schiff, Michael H.
    Fleischmann, Roy
    Valente, Robert
    van der Heijde, Desiree
    Citera, Gustavo
    Zhao, Cathy
    Maldonado, Michael A.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S1031 - S1031
  • [3] Head-to-Head Comparison of Subcutaneous Abatacept Versus Adalimumab in the Treatment of Rheumatoid Arthritis: Key Efficacy and Safety Results from the AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) Trial
    Maldonado, Michael
    Weinblatt, Michael
    Schiff, Michael
    Fleischmann, Roy
    Valente, Robert
    Van der Heijde, Desiree
    Citera, Gustavo
    Zhao, Cathy
    JOURNAL OF RHEUMATOLOGY, 2013, 40 (06) : 1005 - 1006
  • [4] A cost-efficacy comparison of adalimumab and etanercept in the treatment of rheumatoid arthritis
    Malone, DC
    Singh, A
    Wanke, LA
    Ortmeier, BG
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 537 - 537
  • [5] A Cost per Responder Model for Abatacept versus Adalimumab Among Rheumatoid Arthritis Patients with Seropositivity
    Park, Sang Hee
    Han, Xue
    Lobo, Francis
    Nanji, Sakina
    Patel, Dipen
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2020, 12 : 589 - 594
  • [6] Subcutaneous abatacept for the treatment of rheumatoid arthritis
    Schiff, Michael
    RHEUMATOLOGY, 2013, 52 (06) : 986 - 997
  • [7] Cost-efficacy comparison of adalimumab and etanercept in the treatment of rheumatoid arthritis.
    Singh, A
    Wanke, LA
    Malone, DC
    Ortmeier, BG
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S461 - S461
  • [8] HEAD-TO-HEAD COMPARISON OF SUBCUTANEOUS ABATACEPT VS ADALIMUMAB IN THE TREATMENT OF RHEUMATOID ARTHRITIS: KEY EFFICACY AND SAFETY RESULTS FROM THE AMPLE TRIAL
    Weinblatt, Michael E.
    Schiff, Michael H.
    Fleischmann, Roy
    Valente, Robert
    van der Heijde, Desiree
    Citera, Gustavo
    Zhao, Cathy
    Maldonado, Michael A.
    RHEUMATOLOGY, 2013, 52 : 45 - 46
  • [9] Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial
    Schiff, Michael
    Weinblatt, Michael E.
    Valente, Robert
    van der Heijde, Desiree
    Citera, Gustavo
    Elegbe, Ayanbola
    Maldonado, Michael
    Fleischmann, Roy
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (01) : 86 - 94
  • [10] COST-MINIMIZATION ANALYSIS OF SUBCUTANEOUS ABATACEPT IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN SPAIN
    Ariza-Ariza, R.
    van Walsem, A.
    Canal Fontcuberta, C.
    Roldan Acevedo, C.
    Betegon Nicolas, L.
    Oyagueez Martin, I
    Janssen, K.
    VALUE IN HEALTH, 2013, 16 (07) : A564 - A564
12345